Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 47.65% | 30.48% | 51.66% | 61.42% | 53.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.45% | 17.09% | 20.06% | 26.40% | 40.61% |
| Operating Income | -25.50% | -17.09% | -20.06% | -26.40% | -40.61% |
| Income Before Tax | -27.16% | -9.74% | -12.85% | -18.80% | -32.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.16% | -9.74% | -12.85% | -18.80% | -32.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.16% | -9.74% | -12.85% | -18.80% | -32.29% |
| EBIT | -25.50% | -17.09% | -20.06% | -26.40% | -40.61% |
| EBITDA | -25.23% | -16.74% | -19.83% | -26.21% | -40.52% |
| EPS Basic | -21.18% | 7.15% | 11.34% | 6.72% | -3.56% |
| Normalized Basic EPS | -21.20% | 7.14% | 11.35% | 6.73% | -3.55% |
| EPS Diluted | -21.18% | 7.15% | 11.34% | 6.72% | -3.56% |
| Normalized Diluted EPS | -21.20% | 7.14% | 11.35% | 6.73% | -3.55% |
| Average Basic Shares Outstanding | 4.93% | 18.19% | 27.29% | 27.36% | 27.76% |
| Average Diluted Shares Outstanding | 4.93% | 18.19% | 27.29% | 27.36% | 27.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |